Patricia Zilliox

California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA.

CropDesign NV develops traits for cereal crops. It delivers agronomic traits for the global commercial seed markets. The firm focuses on enhancing grain yield in crops such as corn and rice, and increasing biomass of energy crops. Its platform, TraitMill, lows evaluating the effect of genes on the performance of plants under different growing conditions, including drought and low nutrient stress. The company was founded in 1998 and is headquartered in Zwijnaarde, Blgium.

Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain.

France Biotech Association is an independent association founded in 1997 that brings together healthtech entrepreneurs and their expert partners. The non-profit company is based in Paris, France. The association actively contributes to meeting the many challenges of the healthtech industry, such as companies' financing, innovation-related taxes, regulatory and market access related issues. It offers concrete competition and solutions through its commissions and working groups to help startups and SMEs become international leaders capable of rapidly developing and bringing innovative solutions to patients. The French company was founded by Philippe Pouletty, Pascal Brandys, Denis J. Lucquin.

INSERM Transfert Initiative SAS is a venture capital fund that invests in companies located in France. It targets startups from the life sciences and biotechnology sectors, developing new medical practices with a strong intellectual property. It invests between €1 million and €3 million per company during mostly at pre-seed, seed and early-stages.

Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada.

Immutep SAS specializes in biotechnology research and development. It develops immunotherapy treatments for cancer and autoimmune diseases. The company was founded by Frédéric Triebel on October 17, 2001 and is headquartered Orsay, France.

Minka Therapeutics SA develops therapeutic products and diagnostic complementary to current antiretroviral therapy in the treatment of AIDS. The firm provides therapeutic and diagnostic solutions for diseases linked to the immune system through its research on immune dysregulations. The company was founded by Patrice Debre, Vincent Vieillard, Michel Klein, Joël Crouzet, and Robert L. Murphy in 2008 and is headquartered in Evry, France.

Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California.

Creativenture SA produces and markets wines. It provides its products through Custom Wines, Gusto World and Courage Trading. The company is headquartered in Alleur, Belgium

Metabomed Ltd. operates as a drug discovery company. It focuses in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. The company was founded by Eytan Ruppin, Tomer Shlomi and Eyal Gottlieb in 2013 and is headquartered in Yavne, Israel.

TOPADUR Pharma AG is a Swiss-based biotech company located in Schlieren. TOPADUR is a patient-oriented biotech company that aims to enhance the quality of life through cutting-edge research. The private company is developing a new class of compounds based on their innovative cgmp-enzyme regulation system, which corrects locally cgmp levels. These compounds target high medical needs and can be used to treat several ageing-related diseases resulting from insufficient local blood-circulation. The company was founded in 2015 by Reto Naef, who has been the CEO since then.

Brainever SAS manufactures pharmaceutical products. It develops medicines for nervous system diseases. The company was founded on March 31, 2015 and is headquartered in Paris, France.

DIM3 SA develops decision support application software and medical devices. The firm offers Scorso, an app for the screening and follow-up of disease-related malnutrition; Nutrow, a decision support software for an optimization of clinical nutrition; and Biocorder, a connected clinical mobile assistant. The company was founded by Jean Claude Havaux on September 23, 2004 and is headquartered in Liege, Belgium.

Part of Mediolanum Farmaceutici SpA, Cristalfarma Srl produces pharmaceutical products. The company is based in Milan, Italy and was founded in 2004.

Ncardia SA engages in drug discovery research and development. Its cardiac products encompass hiPSC-derived Pluricyte, Cardiomyocytes, Cor.4U cardiomyocytes and vCor.4U ventricular cardiomyocytes and FibroCor.4U cardiac fibroblasts. The company is headquartered in Gosselies, Belgium.

Incepto Medical SAS develops and distributes artificial intelligent (AI) based medical imaging applications. It offers solutions for computed tomography (CT) scans, chest x-ray, and detections for conditions such as fracture and bowel occlusion. The company was founded by Antoine Jomier, Florence Moreau, Vincent Barrau, Jean Michel Malbrancq, and Gaspard d’Assignies and is headquartered in Paris, France.

AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium.

Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland.

EarlySight SA engages in the development, production, and marketing of imaging solutions for the medical and life science sectors. It focuses primarily on the development of an eye camera for the monitoring of the tissue degenerative process associated with retinal diseases. The company was founded by Timothé Laforest, Mathieu Kunzi, Christophe Moser, and Francine Behar-Cohen in 2019 and is headquartered in Lausanne, Switzerland.

CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017.

AbolerIS Pharma develops therapeutic approaches to induce immune tolerance and preserves useful immune responses in inflammatory, autoimmune, and degenerative diseases. The company was founded by Carole Guillonneau, Ignacio Anegon and François-Xavier Hubert and is headquartered in Nantes, France.

NeuVasQ Biotechnologies SA develops pharmaceutical products to treat neurological disorders by repairing neurovascular function. The company is based in Gosselies, Belgium. The Belgian company was founded in 2021 by Benoit Vanhollebeke.

Adipopharma is a French biotech company that focuses on developing treatments for insulin resistance, type 2 diabetes, and related conditions.

Istituto Gentili Srl is an Italian pharmaceutical company specializing in the oncological and onco-hematological field, and also partners with other companies. The private company is based in Milan, Italy. The company is committed to supporting non-profit associations that focus on solidarity and welcoming, particularly for the protection of children. The company was founded in 1917 by Alfredo Gentili, and the CEO is Alessandro del Bono.